Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Enterprise Value (2016 - 2026)

Ani Pharmaceuticals' Enterprise Value history spans 16 years, with the latest figure at -$285.6 million for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 97.12% to -$285.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$285.6 million, a 97.12% decrease, with the full-year FY2025 number at -$285.6 million, down 97.12% from a year prior.
  • Enterprise Value hit -$285.6 million in Q4 2025 for Ani Pharmaceuticals, down from -$262.6 million in the prior quarter.
  • Over the last five years, Enterprise Value for ANIP hit a ceiling of -$15.3 million in Q3 2021 and a floor of -$285.6 million in Q4 2025.
  • Historically, Enterprise Value has averaged -$137.6 million across 5 years, with a median of -$145.0 million in 2024.
  • Biggest five-year swings in Enterprise Value: plummeted 718.38% in 2021 and later soared 49.45% in 2022.
  • Tracing ANIP's Enterprise Value over 5 years: stood at -$105.3 million in 2021, then soared by 49.45% to -$53.2 million in 2022, then tumbled by 315.38% to -$221.1 million in 2023, then surged by 34.47% to -$144.9 million in 2024, then crashed by 97.12% to -$285.6 million in 2025.
  • Business Quant data shows Enterprise Value for ANIP at -$285.6 million in Q4 2025, -$262.6 million in Q3 2025, and -$217.8 million in Q2 2025.